Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
DHC 2022: ‘Optimale fludarabine-waarde kan doel worden bij CAR-T-celtherapie’
mrt 2022 | Leukemie